Day 1 :
- Injectable & Oral drug delivery | Smart drug delivery Technology | Targeted drug delivery system | Advances in drug delivery system
Italian Institute of technology
Rezvan Jamaledin is a Ph.D. student in Industrial Product and Process Engineering at Federico secondo university. She has received her Master degree from Shahid Chamran University, Ahvaz, Iran. Her field is a vaccine, drug delivery by the microneedles.
Kermanshah University of Medical Sciences, Iran
Dr.Maryam Vaezi,Kermanshah University of Medical Sciences, Iran
Objective: The aim of this study is to investigate the effect of diazepam on isolated hearts of hypothyroid rats.
Methods: Experimental study was conducted on 4 rat groups. (30; n=7-8) including group I (control), group II which was treated with propylthiouracyl (0.1gr/lit in drinking water for 30 days), group III which was received a daily injection of diazepam 0.5mg/kg for 5 days and group IV which was treated with the same protocol as groups II and III. The isolated hearts passed baseline, ischemia and reperfusion. Left ventricular developed pressure, heart rate and rate pressure product (RPP) were calculated. The released lactate dehydrogenase (LDH) was measured in effluent.
Results: RPP significantly decreased in the group II compared with group I and IV (p=0.001) at baseline. Recovery percentage in reperfusion significantly increased in group II versus I and IV (P=0.009, P=0.002 respectively). The LDH in the group II was significantly lower than that of I and II (P=0.014, P=0.004 respectively).
Conclusion: The cardiac function is affected by hypothyroidism including decreased RPP at baseline and increased recovery percentage in reperfusion. Diazepam eliminated these effects, probably through affecting on mitochondrial peripheral benzodiazepine receptors (PBR) densities and cyclic AMP (cAMP) levels.
Ms.Riya Ann Philip,ISF College of Pharmacy, India
3D printing is a manufacturing method in which objects are made by fusing or depositing materials such as plastic, metal, ceramics, powders, liquids, or even living cells—in layers to produce a 3D object. This printing has ample number of applications and has acquired much regard in the medical era. Due to its constantly enhancing standard, the use of this technology on patients has increased immensely. It is also used to produce artificial tissues that can be used for testing drugs for the whole pharmaceutical industry. This process is also called additive manufacturing (AM), rapid prototyping (RP), or solid free-form technology (SFF). The printers are similar to inkjet printers but the end products are different. 3D printing medical devices are classified into three classes, viz., Class I, Class II and Class III including Low Risk Devices, Intermediate Risk Devices and High-Risk Devices respectively. The current applications of this technology in the field of medicine are prevalent in Medical Research, Education and Training and most importantly in Individual Patient Care. There are also several controversies and barriers regarding its safety and security, copyright concerns, patent, regulatory concerns etc. A study by Market Research Future (MRFR) reports that the Global 3D Printing Medical Devices Market is likely to witness exponential growth over the forecast period 2018 to 2023. The market is likely to expand at an approximate CAGR of 18% over the forecast period. In this review, we would like to throw light on the aforementioned technology and its effective application in medical field.
University of Hertfordshire
Mycobacterium tuberculosis is a disease which is prevalent worldwide. A recent computational study concluded that 1,3-diketone compounds may exhibit antibacterial properties suggesting that they could be used to develop novel antitubercular drugs (Muddassar et al, 2010). Other studies have shown the growing importance of 1,3-diketones in organic synthetic chemistry and how derivatives of these compounds are being used to develop antibacterial agents. Based on this information, A method was employed to synthesise four derivates of Muddassar’s 1,3-diketone compound through the use of Baker-Venkataraman’s rearrangement with yields between 37-69% were achieved. Higher yields could have been achieved if reaction mixtures were left to reflux for a full 24 hours. Spectral studies and other analytical techniques were used to characterise compounds 1-4. Compounds 1,2 & 4 were characterised to some degree mostly from NMR spectral studies with compound 2 only being characterised partially by IR spectroscopy and Mass spectroscopy. Full characterisation of these compounds however was inconclusive due to the quality of data acquired and further studies are required. Future work could see more thorough characterisation techniques which may involve more in depth analytical techniques such as two-dimensional NMR. Future studies could carry out synthesis of other diketones in the interest of biological activity studies.
Cloud Pharmaceuticals, Inc., Research Triangle Park, NC, USA 27709
Don Van Dyke is Chief Operating Officer at Cloud Pharmaceuticals. His work in AI began at Bio Image Corporation. The company became the leader in image-based genomics and proteomics under his leadership as VP sales, VP worldwide marketing and sales, general manager, and CEO. The company went public on the NASDAQ.
He has had executive roles at two other similar start-ups and advised more than a dozen start-ups and government agencies. He has been a speaker at the College of William and Mary Business School and the Kenan-Flagler Business School at UNC. He is a graduate of Duke University
Speeding the development of novel drug candidates:
Traditionally, drug discovery and development are very time- and resource-consuming processes. Designing new drugs that bind to a specified protein target requires finding the best molecule in a vast chemical space. With an estimated 1065 stable molecules with a molecular weight below 850 available for exploration; examining this space by direct enumeration and evaluation is prohibitively costly. Cloud Pharmaceuticals’ Quantum Molecular Design (QMD) process enables an efficient and accurate search of this chemical space. QMD uses a combination of reverse engineering and Artificial Intelligence methods to map from a set of desired properties to realistic chemical structures.
Among the desired properties is the ability of a molecule to penetrate the Blood Brain Barrier (BBB.) Cloud has designed a proprietary method for BBB permeability calculation.
QMD’s proprietary technology combines artificial intelligence (AI) and cloud computing to search virtual chemical space which enables the rapid and accurate discovery, design, and development of new therapeutics to improve human health and wellbeing and represents a paradigm shift in computational drug design, with broad applications in drug discovery.
University of Connecticut
Obtained the B.Sc. (Honors) in Chemistry from the University of Peradeniya (Sri Lanka) in 2019.
As an undergraduate worked on a computational research project with Dr. R.J.K.U. Ranatunga on Molecular docking and cell penetrating peptides as drug delivery agents. Joined Prof. Jose Gascon’s laboratory at University of Connecticut (USA) in 2019 to pursue a Ph.D. Currently focusing on siRNA therapeutics and Molecular Modeling of Monolayer Protected Gold Clusters used as biosensors and drug delivery agents.
A major difficulty faced in administering active molecules as therapeutic agents is their inability to reach specified target sites. Discovery of cell penetrating peptides (CPPs) represent a potential breakthrough for the transport of a range of biological cargos. CPPs, which are small peptidic molecules capable of translocating through cell membranes, have received significant attention due to their low cytotoxicity and high transduction efficiency. They are classified as cationic, amphipathic and hydrophobic depending on their physicochemical characteristics. Permeation mechanisms of CPPs are not fully understood. There is evidence for both energy dependent and energy independent pathways.
Here we study four CPPs (penetratin, C6, transportan, and K-FGF) to investigate the effect of synergism of multiple peptides in translocation through DOPC bilayers. Results of all-atom Molecular Dynamics (MD) computer simulations show that all CPPs have stable α-helical secondary structures. Moreover, translocation free energy profiles for a single peptide and multi-peptide systems were constructed through coarse grained MD simulations. Free energy profiles indicate that all CPPs spontaneously adsorb on to the surface of the bilayer and the synergism facilitates the spontaneous adsorption. Furthermore, although none of the peptides showed spontaneous translocation for individual peptides, in the case of C6 and K-FGF, synergism has facilitated translocation by reducing the energy barrier.
University of Honduras.
Professor at the faculty of medical sciences at the Autonomous University of Honduras. Father of coronary angiography of Honduras. Head of the cardiology service of the Military Hospital and head of the hemodynamics section. Researcheremodinámica.Investigador.
Validity of Renal Denervation for the treatment of resistant hypertension. Experience in Honduras.
Approximately 25% of the adult population of the industrialized countries suffers from arterial hypertension. Within this population there is a subgroup that despite an optimal treatment that includes 3 or more classes of drugs at maximum dose persists with high blood pressure figures both in the office and in the 24-hour monitoring. (AMBP). This is a population that represents 4-5% and has a very high risk of complications and cardiovascular, renal and cerebrovascular comorbidities with high mortality. Hence the importance of its detection and control in specialized units of HTA.
From the physiopathological point of view there are subtypes of resistant hypertension where sympathetic hyperactivity plays a central role. Hence the advent of non-pharmacological co-adjuvant therapies that aim to decrease renal sympathetic activity. The most studied and most experienced clinical method is Kidney Sympathetic Denervation with radiofrequency catheter. There are several designs on the market. Despite the good results in the first studies: SYMPLICITY-HTN I and SYMPLICITY-HTN II. There was a slowdown in the use of this treatment as a result of the disappointing results of SYMPLICITY-HTN III.
In this review we make a critical analysis of the SYMPLICITY-HTN III study and review the latest evidence demonstrating the current validity of the method in this specific subgroup of true hypertensive resistant patients, the importance of adequate selection and operator experience. We also show the results of the local experience where we observed a high percentage of responders in relation to the technique used, since from the first cases we used an off-label technique where a greater number of applications are made on average 8 per artery and in Secondary branches smaller than 4 mm. In perspective we analyze the results with multipolar devices of more recent design, their advantages and impact on the results.
Nanjing Medical University and Wuhan Medical University
Dr. Anny SHEN
Managing Director of Bering Scientific Information Ltd, Nanjing China.
Completed her studies at Nanjing Medical University and Wuhan Medical University.
She has 8 years clinical medicine experience working in hospitals specializing in respiratory diseases and has more than 20 years’ experience with international pharmaceutical companies – 5 years at GSK working in clinical research for inhaled products and 14 years at Aptar Pharma, working in pharmaceutical sales and business development and the marketing research of MDIs for asthma and COPD.
Dr. Anny Shen has experience in inhaled device and inhaled drug package and regulated affairs.
She received training and study on FDA / EMA regulator of inhalation products and USP / Ph.Eur for inhalation products.
Since 2011, she started a new challenge to concentrate on Asthma and COPD market research in China and training on inhalation drug regulations, (FDA, EMA, CFDA) pharmacopeia standard, quality, and BE study…
She is also working as a senior consultant for the China inhalation industry.
Dr. Anny Shen is a director of the Inhalation Asia conference organization and a Chairman of the Inhalation Drug Delivery Associationï¼ˆIDDA)
A summary of Asthma and COPD and epidemiological characteristics
Mainland China has a total population of 1.4 billion. The increase of population in Chinese cities, large number of people smoking cigarettes (>300 million smokers and > 150million people suffering from second hand smoking), use of motor cars, rapid industrial expansion and worsening environmental pollution are major causes of human respiratory diseases.
Asthma : There were over 60 million asthma patients in 2019. 0-14 years children’s prevalence has risen by 148% in 20 years in big cities.
COPD: Incidence of COPD is very high in China and there were 100 million patients in 2019.
The incidence of COPD among smokers was 13.7%. It has more than double the prevalence of non smokers.
The incidence of COPD was > 40% for smokers over 60 years of age
The incidence of COPD was 25 % for smokers over 40 years of age.
She is Turkish Patent Attorney. She has thirteen years experience in R&D department of generic pharmaceutical companies. She worked as formulation scientist at the Pharmaceutical Technology Department of Nobel Pharmaceuticals and worked as R&D Project Group Executive at Sanovel Pharmaceuticals. She has on-going PhD in Medicinal and Pharmaceutical Chemistry (Yeditepe University, Faculty of Pharmacy). She is also a Turkish Patent Attorney. She has thirteen years experience in R&D department of generic pharmaceutical companies. She worked as formulation scientist at the Pharmaceutical Technology Department of Nobel Pharmaceuticals and worked as R&D Project Group Executive at Sanovel Pharmaceuticals. Currently, She owns the R&D Manager position at Exeltis Pharmaceuticals.
Fast-dissolving formulations represent excellent opportunities for life cycle management to the pharmaceutical companies. Fast dissolving technologies have many advantages like ease of swallowing, administration without water, quick onset of action for improving both patient convenience and compliance as benefits for the patient; extended life cycle, product differentiation, patent protection as benefits for pharmaceutical companies... But there are some challenges for formulation development studies like taste-masking, disintegration time, moisture sensitivity, friability, packaging and intellectual property issues, especially for the generic companies. The technologies are under patent protection like Zydis ® , Flashtab®, OraSolv® and DuraSolv™, WOWTAB®.... One of the major issues is a taste-masking problem may be overcome with using cyclodextrins, polymer coating, flavoring&sweetening agent, micro encapsulation techniques... There are some modified excipients for providing both taste-masking and productability properties in the formulation like Ludiflash®, Pharmaburst®... From the analytical development point of view, there are a number of different methods from conventional dosage forms which are determined in the Pharmacopoeias. And for comparison and assessment of taste masking, electronic tongue may be a good opportunity which was developed by Alpha
M.O.S. In the sense of generic companies, developing a fast dissolving tablets version of an existing immediate-release product means that the two formulations must be bioequivalent and this can be challenging for in-vivo studies especially if the method of taste masking retards the dissolution rate of the active ingredient after disintegration. What about the future of fast dissolving technologies? Orally disintegrating extended Release (ODT-ER) dosage forms are providing all of the benefits of these two drug delivery technologies in a single pharmaceutical product. And oral rapid films also may be a good alternative, especially for the OTC market.
He is interested in investigation the biological effects of medicinal plants which are traditional used. Am aim to discover, isolate, and purify active phytoconstituents then improve therapeutic effect throw enhancement its delivery, Several phytoconstituents, shown excellent bioactivity in vitro, demonstrate less or no in vivo actions due to their poor lipid solubility or improper molecular size or destruction in gut. a model carrier as liposomal nanoparticles, may present a good solution, this will enhanced bioavailability due to their capacity to cross the lipid rich bio-membranes and to protect phytoconstituents from destruction. nano-liposomal have the capacity to deliver the standardized plant extracts and phytoconstituents through several routes of drug administration. Only a few natural phytoconstituents have been formulated as nano-liposomal. The techniques used for such formulations are patentable and highly profitable, especially in field of Cancer drug development.
Capsaicin, is a naturally occurring alkaloid derived from chillies (Capsicum annuum, Solanaceae) Capsaicin has been attributed pharmacological effects since ancient times, but not until the past twenty years has extensive research been done to determine specific applications, specially anti inflammatory and anticancer activity against different cancer type in-vitro and in-vivo. We will describe here a simple, fast and reproducible method for extraction and purification of capsaicin from the fruit of capsicum annuum with almost high yield, then the encapsulation of Capsaicin in multilamellar vesicles composed of DSPE-PEG 2000 [1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[amino(polyethylene glycol)-2000]], DPPC (Dipalmitoylphosphatidylcholine) and variable amounts of cholesterol. The effect of cholesterol content on nano-liposome size, percentage Capsaicin loading and in vitro drug release profiles will describe. different methods will describe to determine molecular interactions between Capsaicin, cholesterol, DPPC and DSPE-PEG.